XOMA Co. (NASDAQ:XOMA) Director Acquires $134,220.80 in Stock

XOMA Co. (NASDAQ:XOMA) Director Joseph M. Limber acquired 5,243 shares of XOMA stock in a transaction that occurred on Monday, April 7th. The stock was bought at an average price of $25.60 per share, with a total value of $134,220.80. Following the purchase, the director now directly owns 10,000 shares of the company’s stock, valued at approximately $256,000. This trade represents a 110.22 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which can be accessed through this link.

XOMA Stock Performance

NASDAQ:XOMA opened at $19.23 on Tuesday. The company has a current ratio of 7.52, a quick ratio of 7.52 and a debt-to-equity ratio of 1.28. The company has a market capitalization of $230.36 million, a P/E ratio of -5.53 and a beta of 1.00. The firm has a 50-day moving average price of $22.92 and a two-hundred day moving average price of $26.51. XOMA Co. has a twelve month low of $18.35 and a twelve month high of $35.00.

XOMA (NASDAQ:XOMA) last issued its quarterly earnings data on Monday, March 17th. The biotechnology company reported ($0.46) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.17). XOMA had a negative return on equity of 24.95% and a negative net margin of 151.34%. The business had revenue of $8.70 million for the quarter, compared to analysts’ expectations of $8.75 million. As a group, research analysts expect that XOMA Co. will post -1.41 earnings per share for the current fiscal year.

Hedge Funds Weigh In On XOMA

Institutional investors have recently made changes to their positions in the stock. BNP Paribas Financial Markets increased its position in XOMA by 95.0% during the 3rd quarter. BNP Paribas Financial Markets now owns 1,632 shares of the biotechnology company’s stock worth $43,000 after purchasing an additional 795 shares in the last quarter. State Street Corp lifted its holdings in XOMA by 1.2% in the 3rd quarter. State Street Corp now owns 142,857 shares of the biotechnology company’s stock valued at $3,783,000 after purchasing an additional 1,754 shares in the last quarter. Barclays PLC grew its holdings in shares of XOMA by 300.7% during the third quarter. Barclays PLC now owns 11,256 shares of the biotechnology company’s stock worth $298,000 after buying an additional 8,447 shares in the last quarter. Geode Capital Management LLC raised its position in shares of XOMA by 0.6% in the third quarter. Geode Capital Management LLC now owns 182,741 shares of the biotechnology company’s stock valued at $4,840,000 after buying an additional 1,138 shares during the last quarter. Finally, Rhumbline Advisers lifted its stake in shares of XOMA by 18.1% during the fourth quarter. Rhumbline Advisers now owns 11,065 shares of the biotechnology company’s stock valued at $291,000 after buying an additional 1,699 shares during the period. 95.92% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on XOMA shares. HC Wainwright reiterated a “buy” rating and set a $104.00 price target on shares of XOMA in a research report on Friday, March 28th. StockNews.com cut XOMA from a “hold” rating to a “sell” rating in a report on Thursday, April 3rd.

XOMA Company Profile

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.